Background and Objective: The use of low-molecular-weight, nonpeptidic molecules that degrade the interaction between the p53 protein and its negative regulator MDM2 (Murine- double minute colon 2) is a new therapeutic strategy for treatment of various types of cancer. One of these agents is RITA (reactivation of p53 and induction of tumor cell apoptosis) which binds to p53 protein and inhibits formation of p53- MDM2 complex while induces apoptosis in tumor cells by increasing p53 protein levels. The aim of this study was to assess the possible in vitro apoptotic effects of RITA on pre-B ALL NALM-6 cells. Materials and Methods: NALM-6 cells were treated with different concentrations of RITA at different time intervals. The viability of NALM...
Current therapy of medulloblastoma, the most common malignant brain tumor of childhood, achieves 40-...
<p>(A and B) HN30 (wild-type p53) and HN31 (mutated p53) head and neck cancer cells were treated wit...
TP53 is the most commonly mutated gene in head and neck cancer (HNSCC), with mutations being associa...
International audienceBackground: The aim of this study was to evaluate the efficacy of the p53-reac...
The first tumour-suppressor gene to be identified was p53. Reactivation of p53 and induction of tumo...
The tumor suppressor p53 is a transcription factor that is crucial for protecting cells from cancer ...
<div><p>The low frequency of p53 alterations e.g., mutations/deletions (∼10%) in multiple myeloma (M...
The p53 tumor suppressor plays an important role in cell fate decisions upon diverse stress conditi...
The low frequency of p53 alterations e.g., mutations/deletions (∼10%) in multiple myeloma (MM) makes...
Colorectal carcinoma (CRC) is the most common cancer of the gastrointestinal tract with frequently d...
SummaryTargeting “oncogene addiction” is a promising strategy for anticancer therapy. We report a po...
Inactivation of the tumor suppressor p53 is essential for the development and maintenance of cancer...
SummaryWe have previously identified the p53-reactivating compound RITA in a cell-based screen. Here...
Glioblastoma (GB) is the most common and aggressive malignant tumor of the central nervous system. D...
TP53 is the most commonly mutated gene in head and neck cancer (HNSCC), with mutations being associa...
Current therapy of medulloblastoma, the most common malignant brain tumor of childhood, achieves 40-...
<p>(A and B) HN30 (wild-type p53) and HN31 (mutated p53) head and neck cancer cells were treated wit...
TP53 is the most commonly mutated gene in head and neck cancer (HNSCC), with mutations being associa...
International audienceBackground: The aim of this study was to evaluate the efficacy of the p53-reac...
The first tumour-suppressor gene to be identified was p53. Reactivation of p53 and induction of tumo...
The tumor suppressor p53 is a transcription factor that is crucial for protecting cells from cancer ...
<div><p>The low frequency of p53 alterations e.g., mutations/deletions (∼10%) in multiple myeloma (M...
The p53 tumor suppressor plays an important role in cell fate decisions upon diverse stress conditi...
The low frequency of p53 alterations e.g., mutations/deletions (∼10%) in multiple myeloma (MM) makes...
Colorectal carcinoma (CRC) is the most common cancer of the gastrointestinal tract with frequently d...
SummaryTargeting “oncogene addiction” is a promising strategy for anticancer therapy. We report a po...
Inactivation of the tumor suppressor p53 is essential for the development and maintenance of cancer...
SummaryWe have previously identified the p53-reactivating compound RITA in a cell-based screen. Here...
Glioblastoma (GB) is the most common and aggressive malignant tumor of the central nervous system. D...
TP53 is the most commonly mutated gene in head and neck cancer (HNSCC), with mutations being associa...
Current therapy of medulloblastoma, the most common malignant brain tumor of childhood, achieves 40-...
<p>(A and B) HN30 (wild-type p53) and HN31 (mutated p53) head and neck cancer cells were treated wit...
TP53 is the most commonly mutated gene in head and neck cancer (HNSCC), with mutations being associa...